Hutchmed completes Phase 1 drug interaction study for HMPL-453 tartrate tablets
A crossover trial testing itraconazole and rifampin effects on HMPL-453 pharmacokinetics in healthy volunteers has completed.
This week's update covers a single Phase 1 pharmacokinetic study for Hutchmed's HMPL-453.
- HMPL-453 tartrate tablets, a Phase 1 drug-drug interaction study in healthy subjects, is now marked completed. The trial was designed to evaluate the effect of itraconazole, a CYP3A and P-gp inhibitor, and rifampin, a CYP enzyme inducer, on HMPL-453 pharmacokinetics in healthy subjects1, with enrollment: 40 participants (actual)1 and a single site listed at yijishan Hospital, Wuhu, Anhui, China1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.